Evofem Biosciences Past Earnings Performance
Past criteria checks 0/6
Evofem Biosciences's earnings have been declining at an average annual rate of -14.4%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 96.3% per year.
Key information
-14.4%
Earnings growth rate
69.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 96.3% |
| Return on equity | n/a |
| Net Margin | -1,816.0% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Evofem Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 16 | -283 | 110 | 35 |
| 31 Mar 22 | 11 | -192 | 122 | 36 |
| 31 Dec 21 | 8 | -206 | 138 | 33 |
| 30 Sep 21 | 5 | -194 | 138 | 30 |
| 30 Jun 21 | 3 | -150 | 124 | 25 |
| 31 Mar 21 | 2 | -169 | 110 | 20 |
| 31 Dec 20 | 0 | -142 | 87 | 17 |
| 30 Sep 20 | 0 | -114 | 66 | 14 |
| 30 Jun 20 | 0 | -98 | 53 | 16 |
| 31 Mar 20 | 0 | -81 | 40 | 18 |
| 31 Dec 19 | 0 | -80 | 31 | 22 |
| 30 Sep 19 | 0 | -82 | 27 | 28 |
| 30 Jun 19 | 0 | -87 | 27 | 32 |
| 31 Mar 19 | 0 | -75 | 31 | 39 |
| 31 Dec 18 | 0 | -126 | 34 | 43 |
| 30 Sep 18 | 0 | -131 | 33 | 45 |
| 30 Jun 18 | 0 | -188 | 27 | 41 |
| 31 Mar 18 | 0 | -172 | 18 | 33 |
| 31 Dec 17 | 0 | -109 | 12 | 24 |
| 30 Sep 17 | 0 | -103 | 11 | 17 |
Quality Earnings: 1AQ is currently unprofitable.
Growing Profit Margin: 1AQ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1AQ is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare 1AQ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1AQ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 1AQ's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.